$KRRO

FORMELA JEAN FRANCOIS sold $2.5M of KRRO (indirect holdings)

FORMELA JEAN FRANCOIS sold 171,405 indirectly-held shares of Korro Bio, Inc. (KRRO) at an average of $14.34 ($13.95–$14.98, $2.46M total) across 8 trades over 2026-06-22 to 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FORMELA JEAN FRANCOIS
Published Jun 25, 2026, 12:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 12:35 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KRRO
Neutral
medium confidence
Mentioned
$KRRO
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KRRONeutralLow
01

Why it matters

The disclosed open-market sale by a director can modestly influence short-term sentiment, but it is not presented alongside any new clinical, regulatory, or financial development.

02

Market read

Traders may monitor KRRO for follow-on insider activity, but the filing alone is unlikely to drive a major repricing without additional catalysts.

03

What to watch

The article does not state whether the director’s total holdings changed materially beyond the post-transaction figure, nor does it provide context on prior sales frequency.

Relevance 5/10Novelty 5/10Timing: immediately after SEC Form 4 filing (filed 2026-06-24 after-hours)

Background

The article is an SEC Form 4 insider transaction disclosure for Korro Bio, Inc.

Company-level read

Ticker impact

$KRRONeutralMedium confidence
Context

Korro Bio director Formela Jean Francois sold $2.46M of KRRO shares via an open-market sale under a 10b5-1 plan (171,405 shares).

Expected impact

Likely limited near-term impact; any effect should be small and fade unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan and no accompanying operational/financial update in the text.

Market effects

No sector read-through provided; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Korro Bio, Inc.

    Subject of the Form 4 insider transaction; director sold shares under a 10b5-1 plan.

  • FORMELA JEAN FRANCOIS

    Director who executed the open-market sale of KRRO shares.

Related articles

$KRROMed

Korro Bio, Inc. (KRRO): Results of Operations and Financial Condition

Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 4 krro-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update — KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical tria